| Medical and Health Sciences | 2021-2025 | 72 | IT 7 | 99.99 |
| Reproductive Medicine | Lifetime | 74 | IT 7 | 99.57 |
| Obstetrics and Gynecology | Lifetime | 85 | IT 6 | 99.43 |
| Oncology | Lifetime | 625 | IT 24 | 98.77 |
| Reproductive Medicine | 2021-2025 | 1 | IT 1 | 99.94 |
| Obstetrics and Gynecology | 2021-2025 | 2 | IT 1 | 99.95 |
| Oncology | 2021-2025 | 29 | IT 3 | 99.84 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 679 | IT 40 | 91.68 |
| Pathology and Forensic Medicine | 2021-2025 | 339 | IT 16 | 88.12 |
| Genetics | 2021-2025 | 663 | IT 18 | 80.03 |
| Endometrial and Cervical Cancer Treatments | Lifetime | 40 | IT 7 | 99.63 |
| Ovarian cancer diagnosis and treatment | Lifetime | 63 | IT 5 | 99.57 |
| PARP inhibition in cancer therapy | Lifetime | 53 | IT 4 | 99.04 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 49 | IT 9 | 99.15 |
| Colorectal and Anal Carcinomas | Lifetime | 188 | IT 6 | 98.54 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 646 | IT 33 | 98.58 |
| Endometriosis Research and Treatment | Lifetime | 264 | IT 42 | 98.34 |
| Cervical Cancer and HPV Research | Lifetime | 343 | IT 15 | 98.31 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 502 | IT 14 | 95.92 |
| Uterine Myomas and Treatments | Lifetime | 591 | IT 90 | 96.50 |
| BRCA gene mutations in cancer | Lifetime | 811 | IT 30 | 95.34 |
| Testicular diseases and treatments | Lifetime | 593 | IT 36 | 94.69 |
| Chemotherapy-related skin toxicity | Lifetime | 568 | IT 33 | 85.89 |
| Beetle Biology and Toxicology Studies | Lifetime | 702 | IT 33 | 50.77 |
| Colorectal and Anal Carcinomas | 2021-2025 | 1 | IT 1 | 99.76 |
| Endometrial and Cervical Cancer Treatments | 2021-2025 | 2 | IT 2 | 99.97 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 2 | IT 2 | 99.97 |
| PARP inhibition in cancer therapy | 2021-2025 | 1 | IT 1 | 99.88 |
| Cervical Cancer and HPV Research | 2021-2025 | 10 | IT 3 | 99.56 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 2 | IT 1 | 98.29 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 89 | IT 9 | 99.66 |
| BRCA gene mutations in cancer | 2021-2025 | 88 | IT 8 | 96.40 |
| Intraperitoneal and Appendiceal Malignancies | 2021-2025 | 67 | IT 18 | 95.14 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 329 | IT 20 | 96.92 |
| HER2/EGFR in Cancer Research | 2021-2025 | 269 | IT 24 | 95.78 |
| Genetic factors in colorectal cancer | 2021-2025 | 607 | IT 72 | 90.44 |
| Advanced Breast Cancer Therapies | 2021-2025 | 439 | IT 49 | 91.84 |
| Endometriosis Research and Treatment | 2021-2025 | 500 | IT 91 | 90.51 |
| Estrogen and related hormone effects | 2021-2025 | 329 | IT 23 | 84.45 |
| Cancer Mechanisms and Therapy | 2021-2025 | 442 | IT 22 | 82.17 |
| Uterine Myomas and Treatments | 2021-2025 | 683 | IT 137 | 83.09 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 625 | IT 27 | 63.47 |
